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Review
Magnetic Resonance Guided Radiotherapy
for Rectal Cancer: Expanding Opportunities
for Non-Operative Management
Leila T. Tchelebi, MD1 , Paul B. Romesser, MD2, Sebastian Feuerlein, MD3,
Sarah Hoffe, MD4, Kujtim Latifi, PhD4, Seth Felder, MD5,
and Michael D. Chuong, MD6
Abstract
Colorectal cancer is the third most common cancer in men and the second most common in women worldwide, and the
incidence is increasing among younger patients. 30% of these malignancies arise in the rectum. Patients with rectal cancer have
historically been managed with preoperative radiation, followed by radical surgery, and adjuvant chemotherapy, with permanent
colostomies in up to 20% of patients. Beginning in the early 2000s, non-operative management (NOM) of rectal cancer emerged as
a viable alternative to radical surgery in select patients. Efforts have been ongoing to optimize neoadjuvant therapy for rectal
cancer, thereby increasing the number of patients potentially eligible to forgo radical surgery. Magnetic resonance guided
radiotherapy (MRgRT) has recently emerged as a treatment modality capable of intensifying preoperative radiation therapy for
rectal cancer patients. This technology may also predict which patients will achieve a complete response to preoperative therapy,
thereby allowing for more appropriate selection of patients for NOM. The present work seeks to illustrate the potential role
MRgRT could play in personalizing rectal cancer treatment thus expanding the role of NOM in rectal cancer.
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Introduction
Colorectal cancer is the third most common cancer in men and
the second most common in women worldwide. 30% of these
malignancies arise in the rectum and the incidence of rectal
cancer is increasing among patients under the age of 50. The
majority of patients with rectal cancer present with locoregio-
nal disease.1 Since the mid-2000s, management of patients
with locally advanced rectal cancer has been preoperative
radiation therapy (with or without chemotherapy), followed
by radical surgery with total mesorectal excision, and post-
operative systemic chemotherapy.2,3 This approach has
resulted in excellent survival outcomes for most patients, at the
expense of significant impairment in quality of life, primarily
due to the consequences of rectal resection.2-4
Despite advances in surgical technique and perioperative care,
surgery for rectal cancer is associated with significant morbidity,
often permanently impairing quality of life.5,6 While the role of
preoperative radiation therapy has historically been to improve
rates of local control following surgery, 15-50% of patients are
able to achieve a pathological complete response (pCR) to
1 Department of Radiation Oncology, Penn State College of Medicine, Hershey,
PA, USA
2 Department of Radiation Oncology, Memorial Sloan Kettering Cancer
Center, New York, NY, USA
3 Department of Diagnostic Imaging and Interventional Radiology, Moffitt
Cancer Center, Tampa, FL, USA
4 Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
5 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL,
USA
6 Department of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA
Corresponding Author:
Leila Tchelebi, Department of Radiation Oncology, Penn State Cancer









Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
neoadjuvant therapy.7-10 Patients who achieve a pCR have been
shown to have lower rates of local disease recurrence and
improved disease-free and overall survival as compared to patients
with residual disease in the surgical specimen.11-14 These favor-
able outcomes among patients achieving a pCR has led investiga-
tors to question the need for radical surgery in order to improve
patients’ quality of life, primarily through rectal preservation.
Efforts have been ongoing to optimize neoadjuvant treat-
ment approaches in order to increase response rates to preo-
perative therapy, thereby allowing more patients to pursue
non-operative management (NOM). Researchers have investi-
gated strategies to intensify both systemic and local preopera-
tive therapies. Magnetic resonance guided radiotherapy
(MRgRT) has recently emerged as a radiation treatment mod-
ality which may allow for more optimal delivery of preopera-
tive radiation therapy for rectal cancer patients than what is
currently achievable with computed-tomography based radia-
tion techniques. The present work seeks to review the current
literature regarding the intensification of preoperative therapies
and to highlight the potential role MRgRT may play in the
future. Taken together, these improvements in neoadjuvant
therapy for rectal cancer may allow for a more individualized
approach to treatment in which select patients can safely avoid
the morbidity associated with radical surgery.
Rationale for NOM
While definitive surgery for rectal cancer is the standard of
care, it is associated with significant morbidity. Studies have
shown that surgical technique has a significant impact on
patient-reported quality of life.15-18 Specifically, patients
requiring low rectal anastomoses or a permanent stoma report
the worst outcomes, indicating that surgery is the primary cause
of rectal cancer morbidity in many patients.19,20 Unfortunately,
a permanent stoma is required in up to 20% of patients and a
significant number of temporary stomas are not reversed.21-24
These patients often experience delayed perineal wound heal-
ing and suffer numerous stoma related complications in the
long-term, including leakage, skin toxicity, and parastomal
hernia, in addition to the psychological stress of having a per-
manent colostomy.20 These long-term consequences of surgery
are especially relevant considering that there is an increasing
number of younger patients who are diagnosed with rectal
cancer, many who will be cured.25
With the goal of reducing treatment-related morbidity and
improving long-term quality of life, NOM has emerged as a
promising treatment option for select patients who may poten-
tially be spared the “over-treatment” of rectal resection, partic-
ularly when a stoma is required. NOM was initially proposed
by Habr-Gama et al in 2004 as a viable alternative to radical
surgery in patients who achieved a complete clinical response
to neoadjuvant therapy.26 The authors reported that the 5-year
overall survival for the 72 patients who underwent observation
following a complete clinical response to neoadjuvant therapy
was 100%. Since then, a number of single-institution series and
meta-analyses have corroborated promising oncologic out-
comes with NOM.27-38 The International Watch and Wait
Database Study is the largest dataset of NOM rectal cancer
patients treated at multiple institutions across Europe over the
last 25 years.36 While the 2-year local tumor regrowth rate was
25%, the majority of these patients could be salvaged by sur-
gery, resulting in a 5-year overall survival rate of 85%.36 The
recently reported OPRA trial, randomizing patients to either
induction (before chemo-radiation) or consolidative (after
chemo-radiation) chemotherapy in patients with locally
advanced rectal cancer, reported organ preservation rates of
43% and 58%, respectively.8 A summary of the data in support
of NOM is shown in Table 1. While there are a number of
ongoing trials evaluating NOM (Table 2), its utilization is
likely to remain controversial until more data is able to confirm
the oncologic safety of this compared to radical resection.
Table 1. Existing Data in Support of Non-Operative Management of Rectal Cancer.
Author (Reference) Year Published N Median Follow-up (months) LR (%) DR (%) DFS (%) OS (%)
Habr-Gama (26) 2004 71 57.3 2.8 4.2 92# 100#
Maas (28) 2011 21 25 4.7 0 89* 100*
Dalton (31) 2012 6 25.5 0 0 100* 100*
Smith (34) 2012 32 28 18.7 9.4 88* 96*
Li (33) 2015 30 59 6.7 3.3 90# 100#
Smith (32) 2015 18 68.4 5.6 5.6 NR NR
Araujo (35) 2015 42 47.7 11.9 9.5 60.9# 71.6#
Lai (30) 2016 18 49.9 11.1 0 NR 100#
van der Valk (36) 2018 880 39 25.2 8 NR 84.7#
Smith (27) 2019 113 43 19.5 8 75# 73#
Garcia-Aguilar (8)^ 2020 324 25 NR NR NR NR
Abbreviations: N, number of patients; LR, local recurrence, DR, distant recurrence; DFS, disease-free survival, OS, overall survival; NR, not reported.
*: Reported at 2 years.
#: Reported at 5 years.
^: Final results of this trial are not available. Current data was reported for the cohort overall, not for patients undergoing organ preservation and was thus omitted
from the above table.
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Current Limitations to NOM
A major limitation to NOM is that it can only be offered to
patients achieving a clinical response to neoadjuvant therapy.
Thus, efforts are ongoing to optimize both neoadjuvant sys-
temic and local treatments for patients with locally advanced
rectal cancer.
Chemotherapy
Efforts are ongoing to increase pCR rates among patients with
rectal cancer through the intensification of neoadjuvant treat-
ments (Figure 1). A total neoadjuvant therapy (TNT) approach,
delivering all therapies (systemic therapy and radiation ther-
apy) prior to resection, has been explored and has yielded pCR
rates which have reproducibly been higher than neoadjuvant
radiation, with or without chemotherapy, alone. The TIMING
trial showed that increasing the number of cycles of pre-
operative consolidative FOLFOX chemotherapy after chemo-
radiation resulted in an incremental increase in the rate of pCR
(25% vs. 30% vs. 38% for 2, 4, and 6 cycles respectively).39
The recently presented PRODIGE 23 trial, comparing preo-
perative long-course chemo-radiation with or without neoadju-
vant systemic chemotherapy consisting of 6 cycles of modified
FOLFOX, found a more than doubling of the pCR rate with a
TNT approach.10 Additional phase II studies and a number of
meta-analyses have confirmed these findings, with pCR rates
approaching 40%.40-44 Efforts are ongoing to further improve
on these outcomes including the phase II NRG Oncology study
(NRG GI-002; NCT02921256) evaluating the addition of
veliparib or pembrolizumab with combination chemotherapy
and radiation therapy in patients with high risk rectal cancer.
The emerging data suggest that delivering all therapy upfront
results in more patients achieving a complete response, chal-
lenging the accepted standard of reflexive rectal resection for
all non-metastatic locally advanced rectal cancer patients.
Radiation Therapy
Efforts have also been made to intensify neoadjuvant radiation
therapy for rectal cancer with the goal of improving tumor
downstaging. Passoni et al showed that delivering a boost dose
to residual disease (to 54 Gy total) following whole pelvic
radiotherapy resulted in a pCR rate of 35%.45 A meta-
analysis showed that the pCR rate after preoperative radiation
to a dose greater than or equal to 60 Gy was 20%.46 A number
of studies, including a randomized trial, have shown that higher
radiation doses result in increased pathological down-sta-
ging.46-49 Of 51 eligible patients enrolled in a European pro-
spective dose escalation study to 60 Gray in 30 fractions, 40
(78%) had a complete response and underwent observation
with low rates of local regrowth.50 A large population based
study evaluating 3298 patients from the National Oncology
Data Alliance showed a dose-response relationship between
radiation dose escalation and tumor regression.51 Patients
treated to 54 Gy achieved greater tumor downstaging relative
to patients receiving 50.4 Gy, who experienced greater tumor
downstaging relative to patients receiving 45 Gy.51
Despite the promising results seen to date, radiation dose
escalation is limited by the inability to safely deliver high doses
Table 2. Ongoing Trials for Non-Operative Management of Rectal Cancer.
Trial
Number







02008656 USA 8c FOLFOX or 5c CapeOX
followed by CRT
CRT followed by 6c
CapeOX or 8c
FOLFOX
3-yr DFS Adverse events 325 Recruiting






02704520 UK Surgery followed by











01047969 UK CRT followed by chemo if
cCR








Multicenter prospective observational cohort study
including patients with rectal cancer who after a long
course of CRT or a short course of radiation with a long







Abbreviations: USA, United States of America; UK, United Kingdom; c, cyles; FOLFOX, folinic acid, 5-fluorouracil, and oxaliplatin; CapeOx, capecitabine and
oxaliplatin; CRT, chemotherapy with concurrent radiotherapy; Folfirinox, 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; 5-Fu, 5-fluorouracil; DFS, disease-
free survival; NOM, non-operative management; LF, local-failure.
^depending on response to neoadjuvant therapy
* For complete list of secondary outcome measures, please refer to clinicaltrials.gov.
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of radiation therapy to the rectum, while sparing adjacent pel-
vic organs, using current treatment techniques. Organs of the
pelvis, including the target and adjacent organs at risk, have
high reproducibility uncertainty. The inter-fraction and intra-
fraction variability in bladder and bowel filling cannot be ade-
quately assessed and accounted for on standard computed
tomography-based images acquired during radiation treatment.
Moreover, rectal cancer is poorly visualized on computed
tomography images. As a result, current protocols attempting
to escalate dose to the tumor employ generous margins to
account for uncertainties in tumor positioning, resulting in
overlap with potentially large volumes of the small bowel,
bladder, normal rectal mucosa, and anal sphincter mus-
cles.50,52-54 Even through the use of more conformal radiation
techniques, such as intensity modulated radiation therapy
which has been shown to decrease toxicity rates from radiation
therapy,55 dose escalation is limited by set-up uncertainties,
organ motion, and poor-tumor tumor visualization.
Emerging genomic data has suggested distinct biological
differences between rectal adenocarcinoma lesions,56-59 which
may allow for a more tailored radiotherapy dose escalation. A
genome-based model for tailoring radiotherapy dose has
explored adaptive dosing to overcome individual rectal tumor
intrinsic radiosensitivities.60,61 Despite this preliminary evi-
dence, radiobiologic data is not currently available for clinical
use to personalize the radiation dose in an attempt to increase
tumor response. Current radiation dose prescriptions are mostly
uniform and do not take into account the tumor’s genomic
makeup or individual tumor biology. Given that patients with
rectal cancer have significant heterogeneity at the genomic
level, the ability to distinguish the individual intrinsic radio-
sensitivity is crucial when considering personalized RT in the
precision medicine era.
Assessing Response to Neoadjuvant Therapy
In addition to the challenges faced in achieving a complete
clinical response to therapy using current treatment techniques,
the interpretation of what constitutes a complete clinical
response limits the broader implementation of a NOM
approach. Clinical complete responders are currently identified
by a combination of clinical, endoscopic, and radiographic
criteria, none of which have been validated on a large-scale.
Thus, it is unknown if clinical complete response accurately
predict pathological complete response.62 Efforts are therefore
ongoing to optimize our ability to assess tumor response to
neoadjuvant therapy through the use of imaging techniques
including MRI and FDG-PET.63-66
Functional MRI using sequences such as diffusion-weighted
imaging (DWI) and dynamic contrast enhanced (DCE) ima-
ging, can provide biological data on tumor response to treat-
ment. Studies have shown that changes in apparent diffusion
Figure 1. Timeline depicting advances in neoadjuvant approaches in conjunction with advances in NOM for rectal cancer patients. Abbre-
viations: NOM, non-operative management; TNT, total neoadjuvant therapy; MRgRT, magnetic resonance guided radiation therapy.
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coefficients (ADC) of rectal carcinoma obtained during CRT
for rectal cancer correlate with tumor down-staging on pathol-
ogy at the time of surgery.67-69 An ongoing European trial
(TRIGGER trial) has incorporated MRI-based tumor regres-
sion grading at 4-6 weeks following completion of neoadjuvant
chemo-radiation to determine response and subsequent man-
agement, including addition of chemotherapy or deferral of
surgery.70 Thus, not only does pretreatment therapy need to
be optimized in order to expand the proportion of rectal cancer
patients eligible for organ preservation, but strategies to appro-
priately and reliably select patients for NOM are also required.
The Potential Role of Magnetic Resonance
Guided Radiotherapy in NOM
On-board real-time Magnetic Resonance Imaging (MRI)-
guided radiation therapy (MRgRT) has emerged as a promising
technology that may facilitate safe tumor dose escalation in
order to further optimize preoperative rectal cancer therapy.
Unlike traditional image guidance which uses on-board cone-
beam computed tomography, MRgRT couples an on-board
MRI with a linear accelerator. MRgRT permits MRI acquisi-
tion immediately before, continuously during, and after a
patient’s radiation treatment, in the treatment position.71 This
temporal sequencing offers a number of advantages. First, MRI
offers superior soft tissue delineation so that the rectal tumor
can be more accurately visualized on daily pre-treatment ima-
ging. Second, the increased soft tissue contrast provides
dynamic anatomical information regarding rectal filling and
subsequently tumor motion during treatment. Third, functional
imaging can provide tumor response data over the course of
treatment and is currently an active area of investigation.
Fourth, on-board MRI can provide daily reassessment and
adaptive re-planning to account for inter-fractional tumor and
normal organ motion.72 Taken together, these features would
allow for improved target accuracy, dose escalation, and
enhanced tumor response assessment for rectal cancer patients
undergoing preoperative radiotherapy using MRgRT.
MRI is the preferred imaging modality used for the initial
local staging of rectal cancer.73 It follows, therefore, that MRI
would also be the best imaging modality for on-board image
guidance during radiation treatment delivery. MR-based ima-
ging would provide the most accurate information on highly
relevant tumor characteristics, such as the relationship to the
mesorectal fascia, proximity to adjacent genitourinary struc-
tures, and the position of clinically suspicious lymph nodes,
which would allow for a reduction in margins added to account
for setup uncertainty. These margins could be further reduced
through the use of adaptive re-planning during the course of
treatment, made possible by the superior spatial resolution
offered by MRgRT.74 Data on the use of MRgRT for pancreatic
cancer has shown that adaptive re-planning results in superior
target coverage and increased organ at risk sparing, allowing
for the delivery of increasing doses of radiation to the target
volume.75,76
MRgRT may also allow for the acquisition of functional
imaging to not only guide treatment but also to assess response.
MRgRT allows daily acquisition during treatment and may
provide data which can be used to generate response prediction
models during the course of radiotherapy.52,77 This innovative
personalized approach to the treatment of rectal cancer might
be used to better select patients who may safely avoid surgery.
Furthermore, functional imaging may allow the radiation dose
to be individualized if, for example, a particular ADC level
were the goal of treatment rather than adhering to a pre-
specified, empiric radiation dose.71 Similarly, MRgRT may
provide radiomic biomarkers to guide radiation dose by identi-
fying physiologically distinct regions within lesions where, for
instance, a pCR may have been achieved. Although radiomics
on diagnostic MRI is relatively well-established,78 it is just now
beginning to be explored using MRgRT images.
Clinical data on the use of MRgRT for rectal cancer is
limited. In 2018, Boldrini et al published their experience on
an in silico evaluation of rectal cancer treatment using MRI-
dian, the first commercially available MRI-based linear accel-
erator system from Viewray.79 The authors compared Co-60
IMRT plans with and without the presence of the magnetic
field in 10 consecutive patients receiving neoadjuvant radiation
for rectal cancer to assess if the presence of the magnetic field
would impact dosimetry. The authors found that there were no
relevant differences between the plans with or without the
magnetic field present. Their planning analysis represented the
first proof of concept to verify the possibility of safely using
MR-guided hybrid treatments in patients with rectal cancer.
Their work served as the dosimetric benchmark for the
newer MRIdian system using a 6MV linear accelerator in place
of Co-60.79
Following the experience of Boldrini and colleagues, Chi-
loiro et al published on the first clinical experience with the
MRIdian in rectal cancer treatment also using the earlier Co-60
model.80 The authors analyzed outcomes of 22 patients with
LARC treated with the MRIdian Co-60 system. Most patients
received a simultaneous integrated boost to 55 Gy in 25 frac-
tions with concurrent chemotherapy. An MRI was acquired as
an alignment image and used to define the radiation field. A
cine-MRI gating protocol was used setting a 5% region of
interest at a 3 mm boundary from the clinical treatment volume
to ensure that the target was always in the appropriate position
during beam-on time. The primary endpoint was complete
response rate. Three patients (14%) achieved a complete clin-
ical response and did not undergo surgery. They were alive
without recurrence at the time of the analysis. Of those who
underwent surgery, 16% achieved a complete pathological
response. In total, 27% of patients achieved a complete clinical
or pathological response to treatment.
Daily assessment of MRI tumor response to individualize
the radiation dose is of significant clinical interest, particularly
in advancing rectal organ preservation research efforts. MRI
imaging parameters may also select out patients who are not
candidates from a primary non-surgical approach and are best
served with preoperative intent. Yet, what still remains
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unknown at this time are at what time point and how best to
measure individual tumor response to therapy. Data from a 15
patients prospectively studied in Europe on a 3 T MRI measur-
ing weekly response suggested that reduction in gross tumor
volume burden occurs as early as week 1 with the main tumor
regression occurring during the first half of a 5-6 week course
of therapy.81 This preliminary research suggests that there may
be an advantage to a sequential boost to the most radioresistant
portion of the tumor can be targeted.
While there are many potential advantages of incorporating
MRgRT into a personalized treatment approach, there are also
some important limitations to be recognized. One of the most
significant challenges associated with MRgRT is increased
treatment time as compared to treatment on a conventional
linear accelerator, which is inconvenient for both patient and
treatment facility. Patients must lay motionless for up to 1.5
hours for treatment if adaptive re-planning is required, lessen-
ing the compliance of individual patients to tolerate the stan-
dard 5.5 week course of treatment. The MRgRT process entails
delivery by step and shoot IMRT with static beams, while a
much quicker Volumetric Modulated Arc Therapy plan may be
delivered on a conventional linac.82 This mode of delivery
lengthens treatment since more beams may be required to
achieve a clinically acceptable plan, significantly increasing
the time on the treatment table. For those patients requiring a
real time adaptive re-plan on the MRI linac, additional time is
needed to recontour the normal organs (10-15 minutes), re-
optimize the dose, evaluate the new plan, perform real time
quality assurance, and then treat. Re-contouring is especially
time consuming because the current treatment planning system
uses deformable image registration to deform the initial con-
tours to the image of the day. These contours require significant
manual edits that require excess physician time. Eventually,
implementation of an artificial intelligence system may be used
to accurately re-contour the normal tissues daily which would
save considerable time in the future.83 For rectal cancer
patients with rectal/urinary urgency, extended time on the treat-
ment table may cause additional discomfort and distress.
In addition to increased treatment planning and delivery
time, there are other limitations to MR-guided therapy which
should be considered as well. One of these is machine down-
time. While this is not an infrequent occurrence on a conven-
tional treatment machine as well, down-time on an MR-linac
may be significantly prolonged. Since the magnet is co-located
within the linac, engineers will need additional time for repairs,
translating to days, rather than hours, of patient delays. Finally,
given the prolonged treatment time on the MR linac, fewer
patients can be treated each day. Thus, patients’ start of therapy
may be substantially delayed until there is availability on the
machine for their treatment to be scheduled, which could lead
to potentially worse outcomes.
These technical challenges with MRgRT require careful
selection of those patients who will benefit the most from such
a time intensive modality. Unanswered questions include
whether MRgRT should be reserved for delivery of the boost
only or in the setting of recurrent rectal cancer. Thus, while the
scientific advantages are compelling, these must be balanced
with the pragmatic issues relating to treatment using this tech-
nology. Future work is needed to explore how best to integrate
MRgRT into the rectal cancer treatment paradigm.
Conclusions and Future Directions
The growing evidence in support of total neoadjuvant therapy,
coupled with the implementation of strategies to enhance the
delivery of local therapy, holds promise for increasing the rate
of organ preservation in rectal cancer patients. Enhanced
response to neoadjuvant therapy together with more appropri-
ate patient selection, through the use of genomic data and func-
tional imaging, may lead to more widespread implementation
of NOM. This more personalized approach to therapy may
permit an increasing number of patients to avoid the morbidity
associated with radical surgery. Efforts are needed to appro-
priately define the optimal use of MRgRT in the management
of these patients and will likely require multi-institutional col-
laborative efforts.
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